𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of 13-cis-retinoic acid plus interferon-α in recurrent head and neck cancer

✍ Scribed by Narin Voravud; Scott M. Lippman; Randal S. Weber; Gladys I. Rodriquez; Douglas Yee; Isaiah W. Dimery; Charles L. Earley; Daniel D. Hoff; Waun Ki Hong

Publisher
Springer US
Year
1993
Tongue
English
Weight
337 KB
Volume
11
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II pilot trial of 13-cis retinoi
A Phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma
✍ Felix H. Brembeck; Klaus Schoppmeyer; Ursula Leupold; Costel Gornistu; Volker Ke 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## BACKGROUND. Advanced unresectable pancreatic adenocarcinoma has a dismal prognosis. The authors previously have shown that retinoic acid (RA) and interferon-␣ (IFN-␣) inhibit growth and induce differentiation in human pancreatic carcinoma cells in vitro and in vivo. The purpose of this trial wa

Phase II clinical trial of 13-cis-retino
Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma
✍ Peter C. Enzinger; David H. Ilson; Leonard B. Saltz; Lisa K. Martin; David P. Ke 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

## BACKGROUND. Interferon in combination with 5-fluorouracil has been shown to be active in squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus. 13-cis-retinoic acid (CRA) has chemopreventive activity in SCC of the head and neck, and, in combination with interferon, has antitumo

Combination of alpha-interferon 2a (α-IF
Combination of alpha-interferon 2a (α-IFN 2a) and 13-CIS-retinoic acid (13cRA) in recurrent, pre-treated squamous-cell carcinoma of head and neck (SCCHN)
✍ S. Toma; M. Airoldi; R. Palumbo; P. Raffo; C. Bumma 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 53 KB 👁 1 views

It is well known that survival of patients with advanced squamous-cell carcinoma of the head and neck (SCCHN) has not significantly improved despite recent advances in radiation and chemotherapy treatment. Specifically, a very low objective response rate can be obtained in patients with recurrent SC